Top2a-KO Mouse
Common Name
Top2a-KO
제품 ID
S-KO-16273
Backgroud
C57BL/6JCya
품종 계통계통 ID
KOCMP-21973-Top2a-B6J-VB
상태
이 마우스 계통을 논문에서 사용할 경우, “Top2a-KO Mouse (카탈로그 번호 S-KO-16273)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Top2a-KO
품종 계통계통 ID
KOCMP-21973-Top2a-B6J-VB
유전자명
제품 ID
S-KO-16273
유전자 별칭
Top-2
배경
C57BL/6JCya
NCBI ID
변형 내용
Conventional knockout
염색체
Chr 11
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000068031
NCBI 전사체 ID
NM_011623
타겟 영역
Exon 6~10
유효 영역 크기
~2.9 kb
유전자 연구 개요
Top2a, also known as DNA topoisomerase II alpha, is a crucial enzyme in DNA replication and cell proliferation [1,3,4,5,6,7]. It resolves topological problems during DNA replication, transcription, and chromatin remodeling, playing a vital role in cell cycle progression. It is associated with multiple signaling pathways such as AKT/mTOR, Wnt/β -catenin, and NF -κB, which are involved in various biological processes and disease development [1,5,8]. Genetic models, especially knockout (KO) and conditional knockout (CKO) mouse models, have been used to study its functions.
In ovarian cancer, TOP2A knockdown inhibited cell proliferation, with cells entering G1 phase arrest and apoptosis, and it was confirmed to regulate cell proliferation and cell cycle through the AKT/mTOR pathway in rescue assays. Mouse model experiments further affirmed its role as a driver of ovarian cancer cell proliferation [1]. In hepatocellular carcinoma, inhibition of EZH2 and TOP2A in vitro induced cellular senescence and inhibited cell proliferation, and in vivo tumorigenesis assays showed that EZH2 and TOP2A knockdown inhibited tumorigenesis by inducing cellular senescence [2]. In medulloblastoma, knockdown of TOP2A inhibited cell proliferation, migration, and invasion, and reduced radioresistance. The Wnt/β -catenin signaling pathway may be involved in these processes [5]. In hepatocellular carcinoma, silencing TOP2A enhanced cells' sensitivity to regorafenib, and TOP2A inhibition by doxorubicin or epirubicin synergized with regorafenib to suppress the growth of sorafenib-resistant tumors [6]. In mice, TOP2A-deficient embryos had impaired trophectoderm differentiation, embryonic mitochondrial function, and developmental rate [9].
In conclusion, model-based research has revealed that Top2a is essential for DNA replication, cell proliferation, and cell cycle regulation. KO/CKO mouse models have contributed to understanding its role in diseases such as ovarian cancer, hepatocellular carcinoma, medulloblastoma, and recurrent spontaneous abortion. These findings provide insights into potential therapeutic strategies targeting Top2a in these disease areas.
References:
1. Zhang, Kaiwen, Zheng, Xingyu, Sun, Yiqing, Tian, Wenyan, Wang, Yingmei. 2024. TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation. In Cancer biology & therapy, 25, 2325126. doi:10.1080/15384047.2024.2325126. https://pubmed.ncbi.nlm.nih.gov/38445610/
2. Wang, Ke, Jiang, Xunliang, Jiang, Yu, Li, Jipeng, Zhang, Rui. 2023. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A. In Journal of experimental & clinical cancer research : CR, 42, 320. doi:10.1186/s13046-023-02855-2. https://pubmed.ncbi.nlm.nih.gov/38008711/
3. Borella, Fulvio, Fucina, Stefano, Seminara, Ylenia, Marozio, Luca, Cosma, Stefano. 2024. Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications. In Current oncology (Toronto, Ont.), 31, 8054-8074. doi:10.3390/curroncol31120594. https://pubmed.ncbi.nlm.nih.gov/39727717/
4. Tian, Tian, Bu, Min, Chen, Xu, Li, Qing, Huang, Jun. 2020. The ZATT-TOP2A-PICH Axis Drives Extensive Replication Fork Reversal to Promote Genome Stability. In Molecular cell, 81, 198-211.e6. doi:10.1016/j.molcel.2020.11.007. https://pubmed.ncbi.nlm.nih.gov/33296677/
5. Zhang, Yufeng, Yang, Haiyan, Wang, Liwen, Xiao, Zhiqing, Xue, Xiaoying. 2022. TOP2A correlates with poor prognosis and affects radioresistance of medulloblastoma. In Frontiers in oncology, 12, 918959. doi:10.3389/fonc.2022.918959. https://pubmed.ncbi.nlm.nih.gov/35912241/
6. Wang, Zongwen, Zhu, Qiankun, Li, Xiaodong, Dong, Xiaoqun, Zhai, Bo. 2022. TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib. In American journal of cancer research, 12, 4343-4360. doi:. https://pubmed.ncbi.nlm.nih.gov/36225636/
7. Wang, Tim, Wei, Jenny J, Sabatini, David M, Lander, Eric S. 2013. Genetic screens in human cells using the CRISPR-Cas9 system. In Science (New York, N.Y.), 343, 80-4. doi:10.1126/science.1246981. https://pubmed.ncbi.nlm.nih.gov/24336569/
8. Fu, Huijia, Tan, Wang, Chen, Zhi, Qi, Hongbo, Liu, Xiru. 2022. TOP2A deficit-induced abnormal decidualization leads to recurrent implantation failure via the NF-κB signaling pathway. In Reproductive biology and endocrinology : RB&E, 20, 142. doi:10.1186/s12958-022-01013-1. https://pubmed.ncbi.nlm.nih.gov/36138481/
9. Duan, Yuhan, Fu, Huijia, Huang, Jiayu, Liu, Linhong, Liu, Xiru. 2022. TOP2A deficiency leads to human recurrent spontaneous abortion and growth retardation of mouse pre-implantation embryos. In Molecular medicine (Cambridge, Mass.), 28, 165. doi:10.1186/s10020-022-00592-4. https://pubmed.ncbi.nlm.nih.gov/36585615/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
